HKSE - Delayed Quote HKD

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (2196.HK)

Compare
13.300
-0.040
(-0.30%)
At close: 4:08:28 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
41,611,309.535
41,399,539.588
43,951,546.895
39,011,184.282
30,306,981.264
Cost of Revenue
21,705,387.138
21,595,308.757
23,169,690.420
20,229,784.681
13,733,528.780
Gross Profit
19,905,922.397
19,804,230.831
20,781,856.476
18,781,399.601
16,573,452.484
Operating Expense
17,155,771.780
18,240,906.771
17,145,016.826
16,071,626.609
13,743,289.518
Operating Income
2,750,150.617
1,563,324.061
3,636,839.649
2,709,772.992
2,830,162.966
Net Non Operating Interest Income Expense
-1,095,835.929
-997,350.084
-709,762.380
-618,688.816
-699,483.238
Pretax Income
3,043,677.275
3,264,567.879
4,574,381.585
6,042,670.590
4,677,844.351
Tax Provision
283,905.747
369,504.452
626,917.465
1,066,401.220
737,864.579
Net Income Common Stockholders
2,113,842.244
2,386,265.814
3,730,804.583
4,728,710.527
3,662,812.938
Basic EPS
0.78
0.89
1.43
1.85
1.43
Diluted EPS
0.78
0.89
1.43
1.85
1.43
Basic Average Shares
2,700,794.034
2,681,197.544
2,608,954.254
2,556,059.745
2,561,407.649
Diluted Average Shares
2,700,794.034
2,681,197.544
2,608,954.254
2,556,059.745
2,561,407.649
Total Operating Income as Reported
3,072,898.952
3,307,507.905
4,656,656.381
6,302,568.209
4,721,145.274
Total Expenses
38,861,158.918
39,836,215.527
40,314,707.246
36,301,411.290
27,476,818.298
Net Income from Continuing & Discontinued Operation
2,113,842.244
2,386,265.814
3,730,804.583
4,728,710.527
3,662,812.938
Normalized Income
3,394,842.528
3,072,203.211
6,069,937.752
5,195,654.896
3,383,792.374
Interest Income
377,741.777
363,645.386
282,634.639
233,727.097
199,608.714
Interest Expense
1,445,036.898
1,324,830.526
963,806.918
822,534.029
880,952.446
Net Interest Income
-1,095,835.929
-997,350.084
-709,762.380
-618,688.816
-699,483.238
EBIT
4,488,714.172
4,589,398.404
5,538,188.503
6,865,204.619
5,558,796.798
EBITDA
4,488,714.172
7,554,583.034
7,874,099.748
8,699,592.892
7,225,018.165
Reconciled Cost of Revenue
21,705,387.138
21,595,308.757
23,169,690.420
20,229,784.681
13,733,528.780
Reconciled Depreciation
--
2,965,184.630
2,335,911.245
1,834,388.272
1,666,221.367
Net Income from Continuing Operation Net Minority Interest
2,113,842.244
2,386,265.814
3,730,804.583
4,728,710.527
3,662,812.938
Total Unusual Items Excluding Goodwill
-1,412,780.521
-773,485.365
-2,710,623.166
-567,009.298
331,274.485
Total Unusual Items
-1,412,780.521
-773,485.365
-2,710,623.166
-567,009.298
331,274.485
Normalized EBITDA
5,901,494.693
8,328,068.400
10,584,722.914
9,266,602.190
6,893,743.680
Tax Rate for Calcs
0.000
0.000
0.000
0.000
0.000
Tax Effect of Unusual Items
-131,780.236
-87,547.969
-371,489.997
-100,064.930
52,253.921
12/31/2020 - 10/30/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

1558.HK HEC CJ PHARM
9.810
+0.41%
 
1513.HK LIVZON PHARMA
25.600
-0.58%
 
3692.HK Hansoh Pharmaceutical Group Company Limited
16.700
+0.36%
 
0460.HK SIHUAN PHARM
0.580
-1.69%
 
0013.HK HUTCHMED
21.250
-9.77%
 
ETST Earth Science Tech, Inc.
0.1599
-0.06%
 
3705.TW YungShin Global Holding Corporation
52.30
-0.57%
 
4105.TWO TTY Biopharm Company Limited
74.90
-0.13%
 
TEVA Teva Pharmaceutical Industries Limited
21.55
+2.72%
 
ITCI Intra-Cellular Therapies, Inc.
127.00
+0.09%